Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Last-ditch plea for "reverse payment" deals ban in US health reform bill

This article was originally published in Scrip

Executive Summary

The US Federal Trade Commission's chairman Jon Leibowitz, along with key Democratic lawmakers from the House of Representatives, have stepped up their call for inclusion of a provision in the healthcare reform legislation that would ban so-called "reverse payment" or "pay-for-delay" deals – the arrangements surrounding patent litigation whereby brand companies allegedly pay off generic competitors in exchange for a delayed generic launch.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts